Stock, pipeline and biotech catalyst intelligence
Market expectations
Street view at a glance
The average target implies 242.1% upsideTargets are estimates—not guarantees—and can change after company updates.Wall Street consensus
BuyCalculated from 11 current ratingsPrice-target range
$14.30Company profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.